Clinical trials: Semaglutide, completed
Obesity, Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study.
- Trial name
- NCT05649137
- Testing
- Semaglutide
- Where
- 76 sites in United States, Bulgaria and 6 more
- Volunteers
- 512 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin.
- Trial name
- NCT05486065
- Testing
- Semaglutide
- Where
- 130 sites in United States, Greece and 3 more
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.
- Trial name
- NCT05579249
- Testing
- Semaglutide, Orlistat, Phentermine/Topiramate
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated with insulin.
- Trial name
- PIONEER 8 (NCT03021187)
- Testing
- semaglutide
- Where
- 118 sites in United States, Canada and 8 more
- Volunteers
- 731 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Obesity
ADJUnct Semaglutide Treatment in Type 1 Diabetes
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
- Trial name
- ADJUST-T1D (NCT05537233)
- Testing
- Semaglutide
- Where
- 4 sites in United States
- Volunteers
- 115 people
- Sponsor
- Viral N. Shah
Type 1 Diabetes
Obesity Treatment to Improve Diabetes
As the obesity pandemic continues unabated, one can expect to see an increase in the prevalence of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in kidney failure, requiring dialysis and renal…
- Trial name
- OTID (NCT05390307)
- Testing
- Liraglutide / Semaglutide, Dapagliflozin, Liraglutide or Semaglutide / Dapagliflozin
- Where
- Kuwait
- Volunteers
- 60 people
- Sponsor
- Dasman Diabetes Institute
Weight Loss, Diabetes Mellitus, Type 2
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.
Introduction: GLP-1 receptor agonists (aGLP1) act increasing pancreatic insulin secretion in response to the glucose, they reduce glucagon secretion and reduce appetite by acting in the central level.
- Conditions
- Weight Loss, Diabetes Mellitus, Type 2, Quality of Life, Safety Issues
- Trial name
- SEVERAL (NCT05136287)
- Testing
- GLP-1 receptor agonist
- Where
- 11 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Jose Seijas Amigo
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2…
- Trial name
- PIONEER 10 (NCT03015220)
- Testing
- Semaglutide, Dulaglutide
- Where
- 34 sites in Japan
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
This is a multicenter, randomized, open, parallel, positive-controlled clinical study to evaluate the efficacy and safety of Semaglutide injection (TQF3510) developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Trial name
- NCT06738979
- Testing
- TQF3510 (Semaglutide Injection), Wegovy®
- Where
- 66 sites in China
- Volunteers
- 408 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 2
A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
The study will look at how insulin 287 and semaglutide work in the body, both when given alone or together. This study will look at the way insulin 287 and semaglutide reach and stay in participants' blood after injection when…
- Trial name
- NCT03789578
- Testing
- NNC0148-0287sema, Semaglutide, NNC0148-0287
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Semaglutide-Induced Gastric Motility, Gastroparesis
Body Surface Gastric Mapping in Patients on Semaglutide
Glucagon-like receptor-1 agonists (GLP-1 RAs), such as Semaglutide (Ozempic), are a class of drugs used for glycemic control in diabetes, and for weight loss and management in obesity.
- Trial name
- NCT06401746
- Testing
- Gastric Alimetry
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- University of Western Sydney
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02146079
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-STEP-HFpEF (NCT06914102)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 58,387 people
- Sponsor
- Brigham and Women's Hospital
Diabetes, Healthy
Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects
This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.
- Trial name
- NCT01619345
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Pneumonia, Aspiration, Anesthesia
Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study
Medicines with peptide-1 receptor agonist action similar to glucagon (GLP-1) are a modern therapeutic option for obesity and diabetes mellitus.
- Trial name
- NCT06154486
- Testing
- semaglutide use
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Hospital Israelita Albert Einstein
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide (NNC0113-0217) in subjects with mild…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02016911
- Testing
- semaglutide
- Where
- 6 sites in Czechia, Poland and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine.
- Conditions
- Overweight, Obesity, Type 2 Diabetes Mellitus
- Trial name
- REDEFINE 2 (NCT05394519)
- Testing
- Cagrilintide, Semaglutide
- Where
- 179 sites in United States, Austria and 11 more
- Volunteers
- 1,200 people
- Sponsor
- Novo Nordisk A/S
Nonalcoholic Steatohepatitis
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause fibrosis improvement and Nonalcoholic Steatohepatitis…
- Trial name
- WAYFIND (NCT04971785)
- Testing
- Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA
- Where
- 242 sites in United States, Australia and 5 more
- Volunteers
- 457 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.
- Trial name
- NCT05144984
- Testing
- NNC0480-0389, Semaglutide
- Where
- 129 sites in United States, Bulgaria and 7 more
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple…
- Trial name
- TRANSITION-T2D (NCT04538352)
- Testing
- Semaglutide, Insulin Degludec, Insulin aspart
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic